UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048883
Receipt number R000055702
Scientific Title Effect and Adverse events of polyethylene glycol preparation combination in constipated patients with severe motor and intellectual disability
Date of disclosure of the study information 2022/09/11
Last modified on 2022/12/20 18:25:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect and Adverse events of polyethylene glycol preparation combination in constipated patients with severe motor and intellectual disability

Acronym

Effect and Adverse events of polyethylene glycol preparation combination in constipated patients with severe motor and intellectual disability

Scientific Title

Effect and Adverse events of polyethylene glycol preparation combination in constipated patients with severe motor and intellectual disability

Scientific Title:Acronym

Effect and Adverse events of polyethylene glycol preparation combination in constipated patients with severe motor and intellectual disability

Region

Japan


Condition

Condition

severe motor and intellectual disability

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A prospective observational study was conducted for examining the effect and adverse events of polyethylene glycol preparation for patients with severe motor and intellectual disabilities (SMID) who have intractable chronic constipation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the number of spontaneous defecation

Key secondary outcomes

the number of usage of cure medicines (e.g. glycerin enema),Stool hardness, adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The drug was administered for 4 weeks,The method of administration was to administer the initial dose to 1 packet at a time, oral or enteral administration once a day for 7 days, and the dose was increased with an interval of 7 days or more depending on the symptoms. The maximum daily dose was limited to 3 packets (2 packets at a time is the maximum).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

19 years-old <=

Age-upper limit

67 years-old >

Gender

Male and Female

Key inclusion criteria

1)Patients over the age of 19 who are hospitalized in severe motor and intellectual disability ward
2)Patients diagnosed with constipation by doctor
3)Patients who are currently prescribed constipation medication but are prescribed cure medicines and use them frequency.

Key exclusion criteria

1)rectal intussuspocion, rectal prolapse, and megacolon inducing constipation
2)mechanical obstruction
3)past history of inflammatory bowel diseases, colorectal cancer, or bowel obstruction
4)physician determined ineligible

Target sample size

10


Research contact person

Name of lead principal investigator

1st name YASUFUMI
Middle name
Last name TSURUSAKI

Organization

National Hospital Organization Higashisaga Hospital

Division name

Department of pharmacy

Zip code

849-0101

Address

7324 Harakoga Miyaki city Miyaki-gun , Saga

TEL

0942942048

Email

tsurusaki.yasufumi.jm@mail.hosp.go.jp


Public contact

Name of contact person

1st name YASUFUMI
Middle name
Last name TSURUSAKI

Organization

National Hospital Organization Higashisaga Hospital

Division name

Department of pharmacy

Zip code

8490101

Address

7324 Harakoga Miyaki city Miyaki-gun , Saga

TEL

0942942048

Homepage URL


Email

tsurusaki.yasufumi.jm@mail.hosp.go.jp


Sponsor or person

Institute

National Hospital Organization Higashisaga Hospital

Institute

Department

Personal name



Funding Source

Organization

National Hospital Organization Higashisaga Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Higashisaga Hospital

Address

7324 Harakoga Miyaki city Miyaki-gun , Saga

Tel

0942942048

Email

tsurusaki.yasufumi.jm@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 09 Month 11 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

12

Results

By administration of MOVICOL, the number of spontaneous defecation was significantly increased (p = 0.04), and the number of usage of cure medicines (e.g. glycerin enema) was decreased (p = 0.03). Stool hardness did not differ before and after MOVICOL administration. No significant adverse events were observed.
MOVICOL can be a new treatment option for patients with SMID who do not respond to conventional therapies for constipation.

Results date posted

2022 Year 12 Month 20 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 09 Month 01 Day

Date of IRB

2020 Year 09 Month 02 Day

Anticipated trial start date

2021 Year 01 Month 14 Day

Last follow-up date

2022 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 09 Month 08 Day

Last modified on

2022 Year 12 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055702


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name